New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
07:37 EDTAEZSAeterna Zentaris announces first patient treated for Phase 2 trial with AEZS-108
Aeterna Zentaris announced that a first patient has been treated for the randomized Phase 2 trial in chemotherapy refractory triple-negative luteinizing hormone-releasing hormone receptor-positive metastatic breast cancer, with the company's targeted doxorubicin peptide conjugate, AEZS-108.
News For AEZS From The Last 14 Days
Check below for free stories on AEZS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
07:33 EDTAEZSAeterna Zentaris' AEZS-134 inhibitor shows positive preclinical data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use